CKD-MBD: Impact on management of kidney disease

Clinical and Experimental Nephrology

Volumn 11, Issue 4, 2007, Pages 261-268

  Ogata, Hiroaki ^a   Koiwa, Fumihiko ^b   Kinugasa, Eriko ^a   Akizawa, Tadao ^c  

^a SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; CKD; CKD MBD; Mineral metabolism; Vitamin D

Indexed keywords

CALCIUM; CINACALCET; SEVELAMER; VITAMIN D DERIVATIVE;

BONE DISEASE; BONE MINERAL; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CALCIUM TRANSPORT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; HUMAN; KIDNEY FUNCTION; NONHUMAN; OSTEITIS FIBROSA; PHOSPHATE BLOOD LEVEL; REVIEW; SECONDARY HYPERPARATHYROIDISM;

ANILINE COMPOUNDS; BONE DISEASES, METABOLIC; CALCIUM METABOLISM DISORDERS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; LANTHANUM; NAPHTHALENES; POLYAMINES; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 37249037181     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-007-0492-5     Document Type: Review

References (91)

1. H Ogata F Koiwa H Ito E Kinugasa 2006 Therapeutic strategies for secondary hyperparathyroidism in dialysis patients Ther Apher Dial 10 355 64
2. M Fukagawa T Akizawa 2006 Calcium abnormalities of dialysis patients J Bone Miner Metab 24 160
3. J Cunningham 2005 Management of secondary hyperparathyroidism Ther Apher Dial 9 Suppl 1 S35 40
4. National Kidney Foundation 2003 K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease Am J Kidney Dis 42 Suppl 3 S1 S201
5. The guideline committee of the Japanese Society for Dialysis Therapy 2006 Guidelines for the management of secondary hyperparathyroidism in chronic dialysis patients J Jpn Soc Dial Ther 39 1435 55
6. Patient Registration Committee. An overview of regular dialysis treatment in Japan as of Dec. 31, 2004. Tokyo: Japanese Society for Dialysis Therapy; 2005
7. EW Young JM Albert S Satayathum DA Goodkin RL Pisoni T Akiba 2005 Predictors and consequence of altered mineral metabolism: the dialysis outcomes practice pattern study Kidney Int 67 1179 87
8. S Moe T Drueke J Cunningham W Goodman K Martin K Olgaard 2006 Definition, evolution, and classification of renal osteodystrophy. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 69 1945 53
9. RN Foley PS Parfrey MJ Sarnak 1998 Epidemiology of cardiovascular disease in chronic renal disease J Am Soc Nephrol 9 12 Suppl S16 23
10. GA Block TE Hulbert-Shearon NW Levin FK Port 1998 Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study Am J Kidney Dis 31 607 17
11. SK Ganesh AG Stack NW Levin T Hulbert-Shearon FK Port 2001 Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients J Am Soc Nephrol 12 2131 8
12. MP Marco L Craver A Betriu M Belart J Fibla E Fernandez 2003 Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population Kidney Int 85 Suppl S111 4
13. GA Block PS Klassen JM Lazarus N Ofsthum EG Lowrie GM Chertow 2004 Mineral metabolism, mortality, and morbidity in maintenance hemodialysis J Am Soc Nephrol 15 2208 18
14. MM Avram R Sreedhara DK Avram RA Muchnick P Fein 1996 Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia Am J Kidney Dis 28 924 30
15. MM Avram N Mittman MM Myint P Fein 2001 Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation Am J Kidney Dis 38 1351 7
16. ML Melamed JA Eustace L Plantinga BG Jaar NE Fink J Coresh 2006 Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study Kidney Int 70 351 7
17. K Amann J Tornig B Kugel ML Gross K Tyralla A El-shakmak 2003 Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia Kidney Int 63 1296 301
18. KR Neves FG Graciolli LM Dos Reis CA Pasqualucci RM Moyses V Jorgetti 2004 Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure Kidney Int 66 2237 44
19. P Jolma P Kööbi J Kalliovalkama H Sara M Fan J Jokihaara 2003 Treatment of secondary hyperparathyroidism by high calcium diet is associated with enhanced resistance artery relaxation in experimental renal failure Nephrol Dial Transplant 18 2560 9
20. P Kööbi TI Vehmas P Jolma J Kalliovalkama M Fan O Niemelä 2006 High-calcium vs high-phosphate intake and small artery tone in advanced experimental renal insufficiency Nephrol Dial Transplant 21 2754 61
21. E Slatopolsky A Brown A Dusso 1999 Pathogenesis of secondary hyperparathyroidism Kidney Int 56 Suppl 73 S14 9
22. S Jono M McKee CE Murry A Shioi Y Nishizawa K Mori 2000 Phosphate regulation of vascular smooth muscle cell calcification Circ Res 87 e10 7
23. P Ducy R Zhang V Geoffroy AL Ridall G Karsenty 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation Cell 89 747 54
24. JL Reynolds AJ Joannides JN Skepper R McNair LJ Schurgers D Proudfoot 2004 Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD J Am Soc Nephrol 15 2857 67
25. K Boström KE Watson S Horn C Wortham IM Herman LL Demer 1993 Bone morphogenetic protein expression in human artherosclerotic lesions J Clin Invest 91 1800 9
26. F Parhami B Basseri J Hwang Y Tintut LL Demer 2002 High-density lipoprotein regulates calcification of vascular cells Circ Res 91 570 6
27. JS Shao SL Cheng JM Pingsterhaus N Charlton-Kachigian AP Loewy DA Towler 2005 Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals J Clin Invest 115 1210 20
28. PA Price JR Buckley MK Williamson 2001 The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin-D-induced calcification of arteries, cartilage, lungs and kidneys in rats J Nutr 131 2910 5
29. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Münter K, et al. Cardiac remodelling in experimental renal failure - an immunohistochemical study. 1998;13:1358-66
30. Amann K, Törnig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63:1296-301
31. N Nagano S Miyata S Obana N Kobayashi N Fukushima SK Bruke M Wada 2003 Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency Nephrol Dial Transplant 18 2014 23
32. K Amann J Törnig C Flechtenmacher A Nabokov G Mall E Ritz 1995 Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH Nephrol Dial Transplant 10 2043 8
33. M Pajda A Matug M Widlak K Antoniak R Ficek J Chudek A Wiecek 2006 Influence of parathyroidectomy on blood pressure and function of the transplanted kidney in patients with tertiary hyperparathyroidism Ann Transplant 11 11 5
34. S Sato M Ohta Y Kawaguchi H Okada M Ono H Saito M Utsunomiya 1995 Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism Miner Electrolyte Metab 21 67 71
35. MR Haussler GK Whitfield CA Haussler JC Hsieh PD Thomson SH Selznick 1998 The nuclear vitamin D receptor: Biological and molecular regulatory properties revealed J Bone Miner Res 13 325 49
36. ME Sandgren M Bronnegard HF DeLuca 1991 Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rats Biochem Biophys Res Commun 181 611 6
37. R Lin JH White 2003 The pleiotropic actions of vitamin D BioEssays 26 21 8
38. M Pfeifer B Begerow HW Minne D Nachtigall C Hansen 2001 Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women J Clin Endocrinol Metab 86 1633 7
39. DA McCarron CD Morris 1985 Blood pressure response to oral calcium in persons with mild to moderate hypertension. A randomized, double-blind, placebo controlled, cross-over trial Ann Intern Med 103 825 31
40. YC Li J Kong M Wei ZF Chen SQ Liu LP Cao 2002 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 229 38
41. W Xiang J Kong S Chen LP Cao G Qiao W Zheng 2005 Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems Am J Physiol Endocrinol Metab 288 125 32
42. PS Parfrey RN Foley JD Harnett GM Kent DC Murray PE Barre 1996 Outcome and risk factors for left ventricular disorders in chronic uraemia Nephrol Dial Transplant 11 1277 85
43. JS Silberberg PE Barre SS Prichard AD Sniderman 1989 Impact of LVH on survival in end-stage renal disease Kidney Int 36 286 90
44. AG Stack R Saran 2002 Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States Am J Kidney Dis 40 1202 10
45. RE Weishaar SN Kim DE Saunders RU Simpson 1990 Involvement of vitamin D3 with cardiovascular function III. Effects on physical and morphological properties Am J Physiol 258 E134 42
46. SG Achinger JC Ayus 2005 The role of vitamin D in left ventricular hypertrophy and cardiac function Kidney Int 67 Suppl 95 S37 42
47. O'Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-Dehydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy 1997;272:H1751-8
48. J Wu M Garami T Cheng DG Gardner 1997 1,25 (OH)2 vitamin D3, and retinoic acid antagonized endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes J Clin Invest 97 1577 88
49. CW Park YS Oh YS Shin CM Kim YS Kim EJ Choi 1999 Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism Am J Kidney Dis 33 37 81
50. E Kinugasa S Koshikawa 2001 Effects of PB-94 (sevelamer hydrochloride), a phosphate binder, on the treatment of hyperphosphatemia in hemodialysis. A randomized, open label, dose-titration study of PB-94 versus Caltan (abstract) J Am Soc Nephrol 12 755A
51. H Tahara Y Tsujimoto T Shoji M Inaba T Tabata Y Nishizawa 2005 Induction of sevelamer hydrochloride and its clinical effects Ther Apher Dial 9 S2 6
52. K Katsumata K Kusano M Hirata K Tsunemi N Nagano SK Brucke N Fukushima 2003 Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats Kidney Int 64 441 50
53. GM Chertow SK Burke P Reggi Treat to Goal Working Group 2002 Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients Kidney Int 62 245 52
54. N Nagano S Miyata S Obana N Kobayashi N Fukushima SK Burke M Wada 2003 Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency Nephrol Dial Transplant 18 2014 23
55. M Cozzolino ME Staniforth H Liapis J Finch SK Burke AS Dusso E Slatopolsky 2003 Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia Kidney Int 64 1653 61
56. M Cozzolino AS Dusso H Liapis J Finch Y Lu SK Burke E Slatopolsky 2002 The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats J Am Soc Nephrol 13 2299 308
57. NG De Santo A Frangiosa P Anastasio A Marino G Correale A Perna 2006 Sevelamer worsens metabolic acidosis in hemodialysis patients J Nephrol 19 Suppl 9 S108 14
58. A Duggal M Hanus E Zhorov R Dagher MA Plone J Goldberg SK Bruke 2006 Novel dosage forms and regimens for sevelamer-based phosphate binders J Ren Nutr 16 248 52
59. AJ Hutchison M Speake F Al-Baaj 2004 Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate Nephrol Dial Transplant 19 1902 6
60. B Lacour A Lucas D Auchere N Ruellan NM de Serre Patey TB Drücke 2005 Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration Kidney Int 67 1062 9
61. AJ Hutchison B Maes J Vanwalleghem G Asmus E Mohamed R Schmieder 2006 Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study Nephrol Clin Pract 102 c61 7
62. T Akizawa Y Ohashi T Akiba M Suzuki Y Nishizawa E Ogata 2004 Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism Ther Apher Dial 8 480 91
63. AJ Brown A Dusso E Slatopolsky 2002 Vitamin D analogues for secondary hyperparathyroidism Nephrol Dial Transplant 17 Suppl 10 10 9
64. T Shoji K Shinohara E Kimoto M Emoto H Tahara H Koyama 2004 Lower risk for cardiovascular mortality in oral 1 alpha-hydroxy vitamin D3 users in a haemodialysis population Nephrol Dial Transplant 19 179 84
65. M Teng M Wolf E Lowrie N Ofsthun JM Lazarus R Thadhani 2003 Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy N Engl J Med 349 446 56
66. F Tentori WC Hunt CA Stidley MR Rohrscheib EJ Bedrick KB Meyer 2006 Mortality risk among hemodialysis patients receiving different vitamin D analogs Kidney Int 70 1858 65
67. U Schwarz K Amann SR Orth A Simonaviciene S Wessels E Ritz 1998 Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats Kidney Int 53 1696 705
68. DD Branisteanu P Leenaert B van Damme R Bouillon 1993 Partial prevention of active Heymann nephritis by 1α,25 dihydroxyvitamin D3 Clin Exp Immunol 94 412 7
69. M Hirata K Makibayashi K Katsumata 2002 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats Nephrol Dial Transplant 17 2132 7
70. K Makibayashi M Tatematsu M Hirata N Fukushima K Kusano S Ohashi 2001 A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis Am J Pathol 158 1733 41
71. V Panichi M Migliori D Taccola C Filippi L De Nisco L Giovannini 2001 Effects of 1,25 (OH) 2D3 in experimental mesangial proliferative nephritis in rats Kidney Int 60 87 95
72. W Krit KV Lemley 1999 The role of the podocyte in glomerulosclerosis Curr Opin Nephrol Hypertens 8 489 97
73. A Kuhlmann CS Haas ML Gross U Reulbach M Holzinger U Schwarz 2004 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat Am J Physiol Renal Physiol 286 F526 33
74. GA Block KJ Martin AL de Francisco SA Turner MM Avram MG Suranyi 2004 Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516 25
75. M Mizobuchi I Hatamura H Ogata F Saji S Uda K Shiizaki 2004 Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency J Am Soc Nephrol 15 2579 87
76. M Wada H Ishii Y Furuya J Fox EF Nemeth N Nagano 1998 NPS R-568 halts or reverses osteitis fibrosa in uremic rats Kidney Int 53 448 53
77. H Ishii M Wada Y Furuya N Nagano EF Nemeth J Foz 2000 Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover and osteomalacia Bone 26 171 82
78. T Odenwald K Nakagawa C Hadtstein F Roesch P Gohlke E Ritz 2006 Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats J Am Soc Nephrol 17 655 62
79. H Ogata E Ritz G Odoni K Amann SR Orth 2003 Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors J Am Soc Nephrol 14 959 67
80. EM Brown M Pollak SC Hebert 1998 The extracellular calcium-sensing receptor: its role in health and disease Annu Rev Med 49 15 29
81. N Nagano 2005 Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism Pharmacol Ther 109 339 65
82. JS Lindberg SM Moe WG Goodman JW Coburn SM Sprague W Li 2003 The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism Kidney Int 63 248 54
83. LD Quarles DJ Sherrard S Adler SJ Rosansky LC McCary W Liu 2003 The calcimimetic AMG073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease J Am Soc Nephrol 14 575 83
84. SM Moe GM Chertow JW Coburn LD Quarles WG Goodman GA Block 2005 Achieving NKF-K/DOQI bone metabolism and disease goals with cinacalcet HCl Kidney Int 67 760 71
85. J Cunningham M Danese K Olson P Klassen GM Chertow 2005 Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism Kidney Int 68 1793 800
86. YH Lien A Sliva D Whittman 2005 Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism Nephrol Dial Transplant 20 1232 7
87. I Lopez E Aguilera-Tejero FJ Mendoza Y Almaden J Perez D Martin M Rodriguez 2006 Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol J Am Soc Nephrol 17 795 804
88. C Charytan JW Coburn M Chonchol J Herman YH Lien W Liu 2005 Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis Am J Kidney Dis 46 58 67
89. M Fukagawa JJ Kazama T Shigematsu 2002 Management of patients with advanced secondary hyperparathyroidism: the Japanese approach Nephrol Dial Transplant 17 1553 7
90. F Koiwa T Kakuta R Tanaka S Yumita 2007 Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism Nephrol Dial Transplant 22 522 8
91. K Shiizaki S Negi I Hatamura T Sakaguchi F Saji K Kunimoto 2005 Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats J Am Soc Nephrol 16 97 108